Stock Taper
SCREENER COMPARE ANY 2 STOCKS
BCAX
BICARA THERAPEUTICS INC. COMMON STOCK
NASDAQ
$23.43
▼ DOWN 5.64% (-1.40)

KEY STATISTICS

Market Cap$1.54 B
52w High$30.99
52w Low$10.29
Dividend Yield—
Frequency—
P/E-7.56
Volume524.73K
Shares Out.65.70M

COMPANY

LEADERSHIP

Claire Mazumdar Clemon
CHIEF EXECUTIVE
Claire Mazumdar Clemon

COMPENSATION 2026

Salary$625,000
Stock Awards$0
Incentive Plan Pay$292,188
All Other Comp.$10,500
Total$927,688

ABOUT

SECTOR
Healthcare
WENT PUBLIC
September 13, 2024
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
103

PRICE TARGET

Target High$42.00
Target Low$20.00
Target Median$35.00
Target Consensus$32.57

UPCOMING EARNINGS

DateNov 9, 2026
DayMonday
Rev. Est.—
NOV
9
MON

PRICE

$23.43 ▼ DOWN 5.64% (−$1.40)
$23.50$24.00$24.509:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM23.43

About Bicara Therapeutics Inc. Common Stock

https://www.bicara.com ↗

Bicara Therapeutics Inc., a Boston-based subsidiary of Biocon, develops bifunctional therapies like ficerafusp alfa for solid tumors, combining EGFR targeting with TGF-β binding, and is a clinical-stage biopharma founded in 2018.

INDUSTRY

Biotechnology

A PRODUCT BICARA THERAPEUTICS INC. COMMON STOCK IS KNOWN FOR

Ficerafusp alfa (BCA101)
Ficerafusp alfa (BCA101)

Ficerafusp alfa, Bicara Therapeutics' lead dual-action antibody targeting EGFR and TGF-β, is an investigational therapy in clinical trials for solid tumors, including head and neck cancer, with FDA Breakthrough Therapy Designation.

COMPETITORS

COMPETITOR
AMGN COMPARE
CGEM COMPARE
JANX COMPARE
LLY COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
120
LISTED HERE
23
RANKED BY POSITION SIZE
VTI
0.00% · 1.7M
XBI
0.24% · 1.2M
XSU.TO
0.03% · 1.1M
SCHA
0.02% · 201.3K
FESM
0.05% · 143.3K
DFAS
0.02% · 138.7K
AVSC
0.06% · 81.0K
SBIO
0.78% · 80.8K
TMSL
0.05% · 59.0K
XRS2.DE
0.03% · 42.8K
LABU
0.17% · 42.5K
CANC
0.42% · 37.5K
RSSL
0.03% · 21.1K
PRFZ
0.01% · 16.0K
BBC
0.69% · 14.5K
GSSC
0.03% · 14.4K
RFLR
0.07% · 2.9K
BIB
0.05% · 2.3K
JDOC
0.37% · 1.5K
WCEO
0.14% · 796
VETS
0.04% · 581
USUE.DE
0.00% · 154
RESM
0.03% · 74

INSTITUTIONAL OWNERSHIP

SHARES OWNED
76.84%
HOLDERS
208
TOP 12 OF 208 · RANKED BY POSITION SIZE
Ra Capital Management, L.P.
7.3M sh · $144.32M
T. Rowe Price Investment Management, Inc.
6.6M sh · $131.39M
Siren, L.L.C.
5.8M sh · $115.42M
Vestal Point Capital, LP
5.4M sh · $107.9M
Deep Track Capital, LP
4.1M sh · $121.73M
Blackrock, Inc.
3.8M sh · $114.25M
Fmr LLC
3.3M sh · $56.33M
Janus Henderson Group Plc
3.3M sh · $66.11M
Red Tree Management, LLC
3.2M sh · $63.06M
Tpg Gp A, LLC
3.0M sh · $59.88M
Omega Fund Management, LLC
2.4M sh · $47.58M
Vanguard Group Inc
2.2M sh · $34.75M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book2
Overall Score2

INSIDER TRADES

★
OFFICER: CHIEF FINANCIAL OFFICER
Larson Jennifer
Purchase · 285.0K shares
2026-08-12
★
OFFICER
Larson Jennifer
— · —
2026-08-12
★
DIRECTOR, OFFICER: PRESIDENT AND COO
Cohlhepp Ryan
Sale · 18.8K shares
2026-08-10
★
OFFICER: CHIEF FINANCIAL OFFICER
Hyep Ivan
Purchase · 12.5K shares
2026-08-10

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 2
NEUTRAL 2
OVERWEIGHT 1
OUTPERFORM 1
EQUAL WEIGHT 1
MARKET OUTPERFORM 1
8 GRADES IN THE LAST 12 MONTHS
BTIG BUY Morgan Stanley OVERWEIGHT Wedbush OUTPERFORM Wells Fargo EQUAL WEIGHT Goldman Sachs NEUTRAL Mizuho NEUTRAL Citizens MARKET OUTPERFORM HC Wainwright & Co. BUY

SECTORS PEERS

PEERPRICE
TNGX$23.34COMPARE
FTRE$18.81COMPARE
SEPN$38.91COMPARE
KURA$12.66COMPARE
MRVI$7.68COMPARE
SVRA$5.26COMPARE
PHAT$9.18COMPARE
PRME$3.61COMPARE